Exploring a new treatment for high blood pressure using remote ischemic conditioning

Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension: a Randomized, Parallel-controlled Clinical Trial

This study is testing a new treatment called remote ischemic conditioning to see if it can help people with high blood pressure feel better when used with their regular medication.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 500 (estimated)
• Ages: 40 Years to 75 Years
• Sex: All
• Sponsor: The First Hospital of Jilin University (other)
• Locations: 1 site (Changchun, Jilin)
• Trial ID: NCT03945305 on ClinicalTrials.gov

What this trial studies

This study investigates the safety and efficacy of remote ischemic conditioning as a treatment for essential hypertension in a community population. It aims to determine how this method can improve vascular function and regulate the body's response to hypertension. Participants will receive standard antihypertensive treatment alongside remote ischemic conditioning to assess its combined effects. The study is particularly relevant given the high prevalence of hypertension and its role as a leading risk factor for stroke.

Who should consider this trial

Good fit: Ideal candidates are individuals aged 40 to 75 with a history of essential hypertension and systolic blood pressure of at least 140 mm Hg.

Not a fit: Patients with severely elevated blood pressure or contraindications to remote ischemic conditioning may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a novel and effective approach to managing essential hypertension.

How similar studies have performed: While remote ischemic conditioning has shown promise in improving vascular health, this specific application for essential hypertension is relatively novel and not extensively tested.

Eligibility criteria

Inclusion Criteria:

1. Age≥40 years, ≤ 75 years, regardless of sex;
2. Having the history of essential hypertension and the systolic blood pressure of at least 140 mm Hg on two consective days;
3. Signed and dated informed consent is obtained

Exclusion Criteria:

1. Blood pressure ≥ 180/110mmHg;
2. Planned adjustment of antihypertensive drugs in the next month;
3. Severe hematologic disorders or significant coagulation abnormalities;
4. Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc;
5. Pregnant or lactating women;
6. Severe hepatic and renal dysfunction, or ALT/AST \>3 times upper limit of normal, or serum creatinine \>265umol/l (\>3mg/dl);
7. Patients being enrolled or having been enrolled in another clinical trial within the 3 months prior to this clinical trial;
8. Patients unsuitable for enrollment in the clinical trial according to the investigator's discretion.

Where this trial is running

Changchun, Jilin

• First Hospital of Jilin University — Changchun, Jilin, China (RECRUITING)

Study contacts

• Study coordinator: Yi Yang, MD,PhD

Conditions: Essential Hypertension, Essential Hypertension, Remote Ischemic Conditioning